Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery

NCT06168799 is registered in ClinicalTrials.gov with AM-Pharma as lead sponsor.

NCT NCT06168799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06168799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery
Lead sponsor
AM-Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2023
Completion date
December 3, 2025
Enrollment
271 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

open heart surgery